ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
Tandem Isotope Therapy with
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 23 citations in OpenAlex.
- Deciphering the phenotypic responses toEuropean journal of nuclear medicine and molecular imaging · 2026Article
- A Preliminary Evaluation ofPharmaceutics · 2026Article
- Enhanced therapeutic efficacy of sequential ¹⁷⁷Lu/²²⁵Ac-LNC1004 FAP-targeted radionuclide therapy combined with anti-PD-L1 blockade in pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [European journal of nuclear medicine and molecular imaging · 2026Article
- Investigating the Theranostic Potential of Elementally Matched [Molecular pharmaceutics · 2026Article
- PretargetedTheranostics · 2026Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- Therapeutic evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- DNA damage repair inhibitors boost targeted radionuclide therapy and immunotherapy of prostate cancer.Apoptosis : an international journal on programmed cell death · 2025Article
- Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Combination prostate-specific membrane antigen-targeted radiopharmaceutical therapy in metastatic prostate cancer.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2025Review
- Individual and Simultaneous Imaging ofIEEE transactions on radiation and plasma medical sciences · 2025Article
- Hematological toxicity of [EJNMMI radiopharmacy and chemistry · 2025Article
- Impact of cell geometry, cellular uptake region, and tumour morphology onEJNMMI physics · 2024Article
- Analysis of Molecular Imaging Biomarkers Derived from [Cancers · 2024Article
- Single Chelator-Minibody Theranostic Agents forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- DNA Damage and Repair in PBMCs after Internal Ex Vivo Irradiation with [International journal of molecular sciences · 2024Article
- Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising option for metastatic castration-resistant prostate cancer. Clinical experience using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.